Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;17(6):349-361.
doi: 10.1038/s41582-021-00486-9. Epub 2021 Apr 20.

Prodromal Parkinson disease subtypes - key to understanding heterogeneity

Affiliations
Review

Prodromal Parkinson disease subtypes - key to understanding heterogeneity

Daniela Berg et al. Nat Rev Neurol. 2021 Jun.

Abstract

In Parkinson disease (PD), pathological processes and neurodegeneration begin long before the cardinal motor symptoms develop and enable clinical diagnosis. In this prodromal phase, risk and prodromal markers can be used to identify individuals who are likely to develop PD, as in the recently updated International Parkinson and Movement Disorders Society research criteria for prodromal PD. However, increasing evidence suggests that clinical and prodromal PD are heterogeneous, and can be classified into subtypes with different clinical manifestations, pathomechanisms and patterns of spatial and temporal progression in the CNS and PNS. Genetic, pathological and imaging markers, as well as motor and non-motor symptoms, might define prodromal subtypes of PD. Moreover, concomitant pathology or other factors, including amyloid-β and tau pathology, age and environmental factors, can cause variability in prodromal PD. Patients with REM sleep behaviour disorder (RBD) exhibit distinct patterns of α-synuclein pathology propagation and might indicate a body-first subtype rather than a brain-first subtype. Identification of prodromal PD subtypes and a full understanding of variability at this stage of the disease is crucial for early and accurate diagnosis and for targeting of neuroprotective interventions to ensure efficacy.

PubMed Disclaimer

References

    1. Mahlknecht, P., Seppi, K. & Poewe, W. The concept of prodromal Parkinson’s disease. J. Parkinson’s Dis. 5, 681–697 (2015). - DOI
    1. Ahmadi, S. A. et al. Analyzing the co-localization of substantia nigra hyper-echogenicities and iron accumulation in Parkinson’s disease: a multi-modal atlas study with transcranial ultrasound and MRI. NeuroImage Clin. 26, 102185 (2020). - PubMed - PMC - DOI
    1. Berg, D. et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov. Disord. 29, 454–462 (2014). - PubMed - PMC - DOI
    1. Savica, R. et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73, 1752–1758 (2009). - PubMed - PMC - DOI
    1. Schrag, A., Horsfall, L., Walters, K., Noyce, A. & Petersen, I. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 14, 57–64 (2015). Very large case–control study that showed higher incidence rates of several autonomic, neuropsychiatric and motor features in individuals 2, 5 and 10 years before diagnosis of PD compared with PD-free individuals using primary care data. - PubMed - DOI

MeSH terms